Efficient virotherapy for osteosarcoma by telomerase-specific oncolytic adenovirus

Journal of Cancer Research and Clinical Oncology

Volumn 137, Issue 6, 2011, Pages 1037-1051

  Li, Guidong ^a,b   Kawashima, Hiroyuki ^a   Ogose, Akira ^a   Ariizumi, Takashi ^a   Xu, Yongjun ^a   Hotta, Tetsuo ^a   Urata, Yasuo ^c   Fujiwara, Toshiyoshi ^d,e   Endo, Naoto ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^b HARBIN MEDICAL UNIVERSITY   (China)

^c National Institute of Infectious Diseases   (Japan)

^d OKAYAMA UNIVERSITY   (Japan)

^e OKAYAMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Apoptosis; Oncolytic adenovirus; Osteosarcoma; Telomerase; Virotherapy

Indexed keywords

E1A PROTEIN; GREEN FLUORESCENT PROTEIN; MESSENGER RNA; OBP 301; ONCOLYTIC ADENOVIRUS; TELOMELYSIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOLYSIS; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; OSTEOSARCOMA; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; BONE NEOPLASMS; CELL LINE, TUMOR; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; ONCOLYTIC VIROTHERAPY; OSTEOSARCOMA; TELOMERASE; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79959770652     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-010-0969-6     Document Type: Article

References (48)

1. Alemany M, Curiel DT (2000) The development of conditionally replicative adenovirus for cancer therapy. Clin Cancer Res 6:3395-3399
2. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johannes A, Fattaey A, McCormick F (1996) An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274:373-376 (Pubitemid 26353341)
3. Chiocca EA (2002) Oncolytic viruses. Nat Rev Cancer 2:938-950
4. Dorfman HD, Czerniak B (1998) Osteosarcoma. In: Dorfman HD, Czerniak B (eds) Bone tumors, 1st edn. Mosby, St. Louis, pp 128-129
5. Fernandes-Alnemri T, Litwack G, Alnemri ES (1994) CPP32, a novel human apoptotic protein with homology to Caenorhabditis elegans cell death protein Ced-3 and mammalian interleukin-1 beta-converting enzyme. J Biol Chem 269:30761-30764 (Pubitemid 24377553)
6. Fueyo J, Gomez-Manzano C, Alemany R, Lee PS, McDonnell TJ, Mitlianga P, Shi YX, Levin VA, Yung WK, Kyritsis AP (2000) A mutant oncolytic adenovirus targeting the RB pathway produces anti-glioma effect in vivo. Oncogene 19:2-12 (Pubitemid 30066345)
7. Fujiwara T, Kagawa S, Kishimoto H, Endo Y, Hioki M, Ikeda Y, Sakai R, Urata Y, Tanaka N, Fujiwara T (2006) Enhanced antitumor efficacy of telomerase-selective oncolytic adenoviral agent OBP-401 with docetaxel: preclinical evaluation of chemovirotherapy. Int J Cancer 119:432-440
8. Fujiwara T, Tanaka N, Nemunaitis JJ, Senzer NN, Tong A, Ichimaru D, Shelby SM, Hashimoto Y, Kawamura H, Urata Y (2008) Phase I trial of intratumoral administration of OBP-301, a novel telomerase-specific oncolytic virus in patients with advanced solid cancer: evaluation of biodistribution and immune response. J Clin Oncol 26:171s
9. Goorin AM, Schwartzentruber DJ, Grier HE, Link MP (2003) Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin Oncol 21:1574-1580 (Pubitemid 46594112)
10. Gu W, Ogose A, Kawashima H, Ito M, Ito T, Matsuba A, Kitahara H, Hotta T, Tokunaga K, Hatano H, Morita T, Urakawa S, Yoshizawa T, Kawashima H, Kuwano R, Endo N (2004) High-level expression of the coxsackievirus and adenovirus receptor messenger RNA in osteosarcoma, Ewing's sarcoma, and benign neurogenic tumors among musculoskeletal tumors. Clin Cancer Res 10:3831-3838
11. Harada JN, Berk AJ (1999) p53-independent and -dependent requirements for E1B-55 k in adenovirus type 5 replication. J. Virol 73:5333-5344 (Pubitemid 29274815)
12. Hashimoto Y, Watanabe Y, Shirakiya Y, Uno F, Kagawa S, Kawamura H, Nagai K, Tanaka N, Kumon H, Urata Y, Fujiwara T (2008) Establishment of biological and pharmacokinetic assays of telomerase-specific replication-selective adenovirus. Cancer Sci 99:385-390 (Pubitemid 351228496)
13. Hatfield L, Hearing P (1991) Redundant elements in the adenovirus type 5 inverted terminal repeat promote bidirectional transcription in vitro and are important for virus growth in vivo. Virology 184:265-276
14. Heise C, Hermiston T, Johnson L, Brooks G, Sampson-Johannes A, Williams A, Hawkins L, Kirn D (2000) An adenovirus E1A mutant that demonstrates potent and selective systemic antitumoral efficacy. Nat Med 6:1134-1139
15. Hioki M, Kagawa S, Fujiwara T, Sakai R, Kojima T, Watanabe Y, Hashimoto Y, Uno F, Tanaka N, Fujiwara T (2008) Combination of oncolytic adenovirotherapy and Bax gene therapy in human cancer xenografted models. Potential merits and hurdles for combination therapy. Int J Cancer 122:2628-2633 (Pubitemid 351590501)
16. Horner MJ, Ries LAG, Krapcho M, Neyman N, Aminou R, Howlader N, Altekruse SF, Feuer EJ, Huang L, Mariotto A, Miller BA, Lewis DR, Eisner MP, Stinchcomb DG, Edwards BK (2009) SEER cancer statistics review, 1975-2006, National Cancer Institute. Bethesda. http://seer.cancer.gov/csr/1975-2006/, based on November 2008 SEER data submission, posted to the SEER web site, 2009. Accessed 10 March 2010
17. Hotta T, Motoyama T, Watanabe H (1992) Three human osteosarcoma cell lines exhibiting different phenotypic expressions. Acta Pathol Jpn 42:595-603
18. Irving J, Wang Z, Powell S, O'Sullivan C, Mok M, Murphy B, Cardoza L, Lebkowski JS, Majumdar AS (2004) Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity. Cancer Gene Ther 11:174-185 (Pubitemid 38280520)
19. Kabeya Y, Mizushima N, Yamamoto A, Oshitani-Okamoto S, Ohsumi Y, Yoshimori T (2004) LC3, GABARAP and GATE16 localize to autophagosomal membrane depending on form-II formation. J Cell Sci 117:2805-2812 (Pubitemid 38997262)
20. Kawashima T, Kagawa S, Kobayashi N, Shirakiya Y, Umeoka T, Teraishi F, Taki M, Kyo S, Tanaka N, Fujiwara T (2004) Telomerase-specific replication-selective virotherapy for human cancer. Clin Cancer Res 10:285-292 (Pubitemid 38114191)
21. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW (1994) Specific association of human telomerase activity with immortal cells and cancer. Science 266:2011-2015
22. Kirn D (2001) Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned? Gene Ther 8:89-98
23. Kirn D, Martuza RL, Zwiebel J (2001) Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nat Med 7:781-787 (Pubitemid 32691631)
24. Kishimoto H, Kojima T, Watanabe Y, Kagawa S, Fujiwara T, Uno F, Teraishi F, Kyo S, Mizuguchi H, Hashimoto Y, Urata Y, Tanaka N, Fujiwara T (2006) In vivo imaging of lymph node metastasis with telomerase-specific replication-selective adenovirus. Nat Med 12:1213-1219
25. Lavoie JN, Nguyen M, Marcellus RC, Branton PE, Shore GC (1998) E4orf4, a novel adenovirus death factor that induces p53-independent apoptosis by a pathway that is not inhibited by zVAD-fmk. J Cell Biol 140:637-645 (Pubitemid 28134066)
26. Leppard KN, Shenk T (1989) The adenovirus E1B 55 kd protein influences mRNA transport via an intranuclear effect on RNA metabolism. EMBO J 8:2329-2336 (Pubitemid 19273312)
27. Lewis IJ, Nooij MA, Whelan J, Sydes MR, Grimer R, Hogendoorn PC, Memon MA, Weeden S, Uscinska BM, van Glabbeke M, Kirkpatrick A, Hauben EI, Craft AW, Taminiau AH MRC, MRC BO06 and EORTC 80931 collaborators; European Osteosarcoma Intergroup (2007) Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma intergroup. J Natl Cancer Inst 99:112-128
28. Li G, Ogose A, Kawashima H, Umezu H, Hotta T, Tohyama T, Ariizumi T, Endo N (2009) Cytogenetic and real-time quantitative reverse-transcriptase polymerase chain reaction analyses in pleomorphic rhabdomyosarcoma. Cancer Genet Cytogent 192:1-9
29. Meyerson M, Counter CM, Eaton EN, Ellisen LW, Steiner P, Caddle SD, Ziaugra L, Beijersbergen RL, Davidoff MJ, Liu Q, Bacchetti S, Haber DA, Weinberg RA (1997) hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 90:785-795 (Pubitemid 27357969)
30. Oliver FJ, de la Rubia G, Rolli V, Ruiz-Ruiz MC, de Murcia G, Murcia JM (1998) Importance of poly(ADP-ribose) polymerase and its cleavage in apoptosis. Lesson from an uncleavable mutant. J Biol Chem 273:33533-33539 (Pubitemid 29005737)
31. Osborne TF, Berk AJ (1983) Far upstream initiation sites for adenovirus early region 1A transcription are utilized after the onset of viral DNA replication. J Virol 45:594-599 (Pubitemid 13225424)
32. Phillips AC, Bates S, Ryan KM, Helin K, Vousden KH (1997) Induction of DNA synthesis and apoptosis are separable functions of E2F-1. Genes Dev 11:1853-1863 (Pubitemid 27315214)
33. Rodriguez R, Schuur ER, Lim HY, Henderson GA, Simons JW, Henderson DR (1997) Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res 57:2559-2563 (Pubitemid 27283756)
34. Scheel C, Schaefer KL, Jauch A, Keller M, Wai D, Brinkschmidt C (2001) Alternative lengthening of telomeres is associated with chromosomal instability in osteosarcomas. Oncogene 20:3835-3844 (Pubitemid 32646194)
35. Shay JW, Bacchetti S (1997) A survey of telomerase activity in human cancer. Eur J Cancer 33:787-791
36. Sluga M, Windhager R, Lang S, Heinzl H, Bielack S, Kotz R (1999) Local and systemic control after ablative and limb sparing surgery in patients with osteosarcoma. Clin Orthop 358:120-127 (Pubitemid 29066081)
37. Sotillo-Piñeiro E, Sierrasesúmaga L, Patiñno- García A (2004) Telomerase activity and telomere length in primary and metastatic tumors from pediatric bone cancer patients. Pediatr Res 55:231-235
38. Takakura M, Kyo S, Kanaya T, Hirano H, Takeda J, Yutsudo M, Inoue M (1999) Cloning of human telomerase catalytic subunit (hTERT) gene for transcriptional activation in immortalized and cancer cells. Cancer Res 59:551-557
39. Takakura M, Nakamura M, Kyo S, Hashimoto M, Mori N, Ikoma T, Mizumoto Y, Fujiwara T, Urata Y, Inoue M (2010) Intraperitoneal administration of telomerase-specific oncolytic adenovirus sensitizes ovarian cancer cells to cisplatin and affects survival in a xenograft model with peritoneal dissemination. Cancer Gene Ther 17:11-19
40. Taki M, Kagawa S, Nishizaki M, Mizuguchi H, Hayakawa T, Kyo S, Nagai K, Urata Y, Tanaka N, Fujiwara T (2005) Enhanced oncolysis by a tropism-modified telomerase-specific replication-selective adenoviral agent OBP-405 ('Telomelysin-RGD'). Oncogene 24:3130-3140 (Pubitemid 40695082)
41. Tsukuda K, Wiewrodt R, Molnar-Kimber K, Jovanovic VP, Amin KM (2002) An E2F-responsive replication-selective adenovirus targeted to the defective cell cycle in cancer cells: potent antitumoral efficacy but no toxicity to normal cell. Cancer Res 62:3438-3447 (Pubitemid 34651390)
42. Ulaner GA, Huang HY, Otero J, Zhao Z, Ben-Porat L, Satagopan JM, Gorlick R, Meyers P, Healey JH, Huvos AG, Hoffman AR, Ladanyi M (2003) Absence of a telomere maintenance mechanism as a favorable prognostic factor in patients with osteosarcoma. Cancer Res 63:1759-1763 (Pubitemid 36469314)
43. Umeoka T, Kawashima T, Kagawa S, Teraishi F, Taki M, Nishizaki M, Kyo S, Nagai K, Urata Y, Tanaka N, Fujiwara T (2004) Visualization of intrathoracically disseminated solid tumors in mice with optical imaging by telomerase-specific amplification of a transferred green fluorescent protein gene. Cancer Res 64:6259-6265 (Pubitemid 39129429)
44. Watanabe T, Hioki M, Fujiwara T, Nishizaki M, Kagawa S, Taki M, Kishimoto H, Endo Y, Urata Y, Tanaka N, Fujiwara T (2006) Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells. Exp Cell Res 312:256-265 (Pubitemid 41814835)
45. Wirth T, Zender L, Schulte B, Mundt B, Plentz R, Rudolph KL, Manns M, Kubicka S, Kühnel F (2003) A telomerase-dependent conditionally replicating adenovirus for selective treatment of cancer. Cancer Res 63:3181-3188 (Pubitemid 36735870)
46. Yew PR, Berk AJ (1992) Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein. Nature 357:82-85
47. Yokoyama T, Iwado E, Kondo Y, Aoki H, Hayashi Y, Georgescu MM, Sawaya R, Hess KR, Mills GB, Kawamura H, Hashimoto Y, Urata Y, Fujiwara T, Kondo S (2008) Autophagy-inducing agents augment the antitumor effect of telomerase-selective oncolytic adenovirus OBP-405 on glioblastoma cells. Gene Ther 15:1233-1239
48. Zheng X, Rao XM, Snodgrass C, Wang M, Dong Y, McMasters KM, Zhou HS (2005) Adenoviral E1a expression levels affect virus-selective replication in human cancer cells. Cancer Biol Ther 4:1255-1262